Treatments for Severe Cutaneous Adverse Reactions
Open Access
- 27 December 2017
- journal article
- review article
- Published by Hindawi Limited in Clinical and Developmental Immunology
- Vol. 2017, 1-9
- https://doi.org/10.1155/2017/1503709
Abstract
Severe cutaneous adverse reaction (SCAR) is life-threatening. It consists of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed drug eruptions (GBFDE). In the past years, emerging studies have provided better understandings regarding the pathogenesis of these diseases. These diseases have unique presentations and distinct pathomechanisms. Therefore, theoretically, the options of treatments might be different among various SCARs. However, due to the rarity of these diseases, sufficient evidence is still lacking to support the best choice of treatment for patients with SCAR. Herein, we will provide a concise review with an emphasis on the characteristics and treatments of each SCAR. It may serve as a guidance based on the current best of knowledge and may shed light on the directions for further investigations.Keywords
Funding Information
- National Taiwan University (105A165, NTUH 106-S3535)
This publication has 96 references indexed in Scilit:
- Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkersJournal of the American Academy of Dermatology, 2013
- Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysisBritish Journal of Dermatology, 2013
- Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysisJournal of the American Academy of Dermatology, 2011
- Toxic epidermal necrolysis and Stevens-Johnson syndromeOrphanet Journal of Rare Diseases, 2010
- Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysisBritish Journal of Dermatology, 2010
- Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-StudyJournal of Investigative Dermatology, 2008
- Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR StudyJournal of the American Academy of Dermatology, 2008
- Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case–control study (EuroSCAR)British Journal of Dermatology, 2007
- Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference?Journal of Burn Care & Rehabilitation, 2004
- Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in childrenEuropean Journal of Pediatrics, 1997